News

Nested Therapeutics Announces Nomination of First Development Candidate, a Potential First-in-Class Inhibitor of the RAS/MAPK Pathway

Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers that were founded on the technology discovered by University researcher Kevan Shokat, PhD, today announced the nomination of the company’s first drug development...

Chroma Medicine Secures $135M in Series B Financing

Chroma, a genomic medicine company pioneering single-dose epigenetic editing therapeutics founded on UCSF research discovered by Luke Gilbert, PhD, and Jonathan Weissman, PhD., today announced the completion of a $135 million Series B financing. The financing will support the advancement of Chroma'...

MindRhythm Initiates Pivotal Portion of Prehospital Stroke Trial

MindRhythm in partnership with Wayne State University School of Medicine in Detroit, Michigan, today announces the conclusion of phase I and initiation of the pivotal portion of its hEadPulse for Ischemic StrOke DEtection Prehospital Study (EPISODE-VS). MindRhythm was co-founded by UCSFs Dr. Wade...

The University of California and Foundery Sign Master Agreement to Translate Novel Discoveries into Transformational Immunotherapies

The unique industry-academic partnership supports UCSF investigator research while creating opportunities for downstream drug development and shared economics. MORE

Long-term functional regeneration of radiation-damaged salivary glands through delivery of a neurogenic hydrogel

Patients battling certain forms of cancer may find their salivary glands are severely depleted after radiotherapy. With no regenerative therapies available, organ dysfunction is irreversible. UCSF professors Chelsea Bahney and Sarah Knox present in 'Science,' their research into neurogenic...

Barry Selick Moves From UCSF To Hinge Bio

Barry Selick, Ph.D., successful biopharmaceutical scientist, senior executive, and entrepreneur, appointed Chief Executive Officer at Hinge Bio.

Rezo Therapeutics to Emerge from Stealth

The team behind Rezo Therapeutics, a new biotech co-founded by a group of University of California, San Francisco, scientists including Natalia Jura, Kevan Shokat, Nevan Krogan, and industry veterans George Scangos and Norbert Bischofberger, was weighing if, and how, to finally come out of stealth...

Increasing the success potential of promising biotech companies

Biotech startups benefit society by solving unmet scientific and medical needs, but more can be done to move their technologies to market more quickly. This month, Program Director Stephanie Marrus of the University of California, San Francisco's Global Entrepreneurship Program, together with John...

Catalyst Awardees Present to Investors at the “Born in California Investor Demo Days”

Several companies funded by the Catalyst Program and launched out of UCSF, including Alessa Therapeutics, Diatiro, Ooney, and Neomer Diagnostics, joined many of the University of California’s best and most investment-worthy startups seeking Seed and Series A investors, to pitch their business to...

ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial in Treatment for Ovarian Cancer

Arsenal Biosciences, Inc., a clinical stage, programmable cell therapy company engineering advanced CAR T cell therapies for solid tumors, founded by UCSF Researchers Alex Marson, PhD, and Kole Roybal, PhD, today announced that the first patient has been dosed with AB-1015 in a Phase 1, first-in-...